Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.58 |
| ▸ | HRH1 | P35367 | 2/20 | 0.56 |
| ▸ | HTR1B | P28222 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3453978 | 0.92 | ALDH1A1 (0.65) | ALDH1A1KMT2APTK2BKDM4EHRH1 | |
| Hydrochloric Acid SCHEMBL15048947 | 0.90 | ALDH1A1 (0.63) | ALDH1A1KMT2APTK2BKDM4EHRH1 | |
| SCHEMBL11811055 | 0.89 | KDM4E (0.56) | ALDH1A1KDM4EHRH1HTR1BSMN1; SMN2 | |
| SCHEMBL16676613 | 0.87 | LMNA (0.66) | ALDH1A1KDM4EHRH1HTR1BHTT | |
| SCHEMBL26210242 | 0.85 | ALDH1A1 (0.56) | ALDH1A1KMT2APTK2BKDM4EHTT | |
| SCHEMBL11334557 | 0.84 | ALDH1A1 (0.66) | ALDH1A1KMT2APTK2BKDM4EHTT | |
| SCHEMBL11343273 | 0.84 | KDM4E (0.63) | ALDH1A1KMT2AKDM4EHRH1HTR1B | |
| SCHEMBL212173 | 0.84 | ALDH1A1 (0.79) | ALDH1A1KMT2APTK2BKDM4EHTT | |
| Hydrochloric Acid SCHEMBL8415688 | 0.84 | ALDH1A1 (0.55) | ALDH1A1KMT2APTK2BKDM4EHTT | |
| SCHEMBL16674534 | 0.83 | KDM4E (0.55) | ALDH1A1KDM4EHRH1HTR1BHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4298603-A | LOCAL ANESTHETICS | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1981-11-03 | — | — | US | claimed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| WO-2003103652-A1 | METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| CN-1136556-A | Aromatic group substituted W-amino alkyl amide and alkyl amide | CIBA GEIGY CO LTD (CH) | 1996-11-27 | — | — | CN | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
| US-4298603-A | LOCAL ANESTHETICS | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1981-11-03 | — | — | US | disclosed |
| EP-0031632-A1 | O-Aminoalkylsalicylates, process for their preparation, and their pharmaceutical compositions | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1981-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | ALDH1A1 4236/4885KMT2A 4371/4885PTK2B 2860/4885 |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | ALDH1A1 1039/4885KMT2A 2309/4885PTK2B 4453/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | ALDH1A1 4236/4885KMT2A 4371/4885PTK2B 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.